The stock of Boston Scientific Corporation (NYSE:BSX) increased by $3.03 on Monday to finish at $53.79, up 5.97 percent. The last five days have seen an average of 9,898,100 shares of common stock traded. 28 times new highs were reached in the current year, with a gain of $7.52. The average number of shares traded over the last 20 days was 7,336,095, while the average volume over the last 50 days totaled 7,028,642.
BSX stock appreciated 4.06% since last month. On 08/08/23, the company’s shares reached a one-month low of $49.69. The stock touched a high of $54.74 on 06/23/23, after rallying from a low of $37.74 in 52 weeks. The price of BSX stock has risen by 16.25% or $7.52 this year, reaching a new high 28 times. Still, the stock price is down -1.74% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
BSX stock investors should be aware that Boston Scientific Corporation (BSX) stock had its last reported insider trading activity 4 days ago on Aug 25. On Aug 25, SVP, GC and Corp. Secretary Brown Vance R sold 15,750 shares at $50.52 each. This transaction resulted in the insider making $795,756. On Aug 21, Butcher Arthur C sold 6,600 shares at a price of US$50.40. After the transaction, the insider now owns 11,396 shares. Director Dockendorff Charles J had earlier sold 17,079 shares on Aug 18 for $50.74 a share. The transaction was completed for $866,631.
Valuation Metrics
Boston Scientific Corporation (BSX) has a trailing price-to-earnings (P/E) ratio of 90.56. Beta for the stock is 0.78. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 5.84, the price-to-book (PB) ratio of 4.27, and the price-to-cash flow ratio of 51.89.
Financial Health
For the three months ended June 29, Boston Scientific Corporation’s quick ratio was 0.80, while its current ratio was 1.30, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.47, and the total debt to equity ratio is 0.50. As far as profitability goes, gross margin for the trailing twelve months is 69.70% percent. Boston Scientific Corporation’s EBITDA margin for the year ended June 29 was 23.34%, whereas its operating margin stood at 13.60% for the same period. Based on annual data, it had gross profit of $8.73 billion and revenue of $12.68 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BSX’s return on assets (ROA) during the last 12 months has been 2.60%. There was a 3.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 4.80%.
Earnings Surprise
According to Boston Scientific Corporation’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.6 billion, while revenues rose by 9.89% to $3.39 billion. It was predicted that Boston Scientific Corporation’s quarterly earnings would be $0.53, but it ended up being $0.49, beating the consensus by 8.20%. EBITDA was $869.0 million for the quarter. At the end of Boston Scientific Corporation’s most recent quarter ended June 29, its liabilities totaled 15.12 billion, while its total debt was $9.45 billion. Equity owned by shareholders amounts to $1.46 billion.
Technical Picture
Here’s a quick look at Boston Scientific Corporation’s (BSX) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 77.16%, suggesting the stock is Overbought, with a 31.51% historical volatility rate.
The stochastic %K and %D were 57.38% and 40.74% respectively, while the average true range (ATR) was 1.06. Based on the 14-day stochastic reading of 95.44%, the RSI (14) reading is 68.14%. On the 9-day MACD Oscillator, the stock is at 0.69, and the 14-day reading is at 0.61.
Analyst Ratings
In its analyst report released on July 19, 2023, Robert W. Baird began covering Boston Scientific Corporation (NYSE: BSX). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Boston Scientific Corporation (BSX) an Buy rating. BSX is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 5 rates it overweight and 23 others recommend it as a buy.
What is BSX’s price target for the next 12 months?
The current consensus forecast for the stock is between $55.00 and $68.00, with a median target price of $60.50. In analyzing these forecasts, the average price target given by analysts for Boston Scientific Corporation (BSX) is $60.50.
